MediSieve founder honoured as MIT Technology Review’s Innovator Under 35
MediSieve is the medical device company developing ‘magnetic blood filtration’. Its technology can potentially transform the treatment of bloodborne diseases including sepsis, leukaemia and malaria in a process that is similar to dialysis. Dr George Frodsham, CEO and founder of MediSieve, has been selected as one of MIT Technology Review’s Innovators Under 35 Europe 2019.
Dr Frodsham said: “It is a real honour to be selected as one of the Innovators Under 35 by such a prestigious institution as MIT. It is further validation of the fantastic work being carried out by the MediSieve team. I am excited to join the community of other innovators from 2019 and previous years and look forward to engaging further with them and MIT.”
Last year was one to remember for MediSieve. The company recently announced that it was a winner of the ‘Breakthrough Medical or Healthcare Device Award’ in the Beanstalks competition 2019. Earlier in the year, Dr Frodsham won the Early Career Impact Award at the BBSRC Innovator of the Year Awards 2019. The company also won the highly competitive award category of Investment Achievement at the MedTech London Awards 2019, part of the annual Mayor of London Awards.
Stago’s objective is to improve the health of as many people as possible by offering powerful biotechnology solutions for blood-based diagnostics.
We take a lean, confidence-building approach to digital connectivity – from our latest Coag.One middleware to our cyber-secure Connect.One capability for enhanced engineering and remote...